Group 1 - The brain-computer interface (BCI) industry has introduced a new standard titled "Technical Requirements and Testing Methods for EEG-based Fatigue State Monitoring Systems," which aims to fill the existing gap in industry standards [1] - The standard was developed by the China Academy of Information and Communications Technology in collaboration with over 30 institutions, including Capital Medical University Xuanwu Hospital, Zhejiang University, and Tsinghua University, to clarify the working principles, structure, technical requirements, and testing methods of relevant systems [1] - Henan Xiangyu Medical Equipment Co., Ltd. played a significant role in drafting the standard, leveraging its expertise in rehabilitation and BCI technology integration [1] Group 2 - The BCI industry is currently experiencing a critical period of technological iteration and expansion of application scenarios, with both invasive and non-invasive technology paths developing concurrently [1] - Invasive technology requires surgical implantation of electrodes for high-precision brain signal acquisition, which limits its scalability due to high risks and costs, while non-invasive technology, such as EEG caps, is safer and more convenient for health monitoring and rehabilitation [2] - The rehabilitation equipment industrial park in Anyang City has attracted 62 upstream and downstream enterprises, including Xiangyu Medical, creating a complete industrial chain that integrates research, manufacturing, and services [2]

Group 1 - The core viewpoint of the article highlights the recent release of the industry standard "Technical Requirements and Testing Methods for Fatigue State Monitoring Systems Based on EEG," which aims to regulate the brain-computer interface (BCI) sector and enhance product stability [1] - The standard was developed by the China Academy of Information and Communications Technology in collaboration with over 30 institutions, including major universities and hospitals, to fill the existing gap in industry standards [1] - Xiangyu Medical, a leading rehabilitation medical company based in Henan, has actively participated in the standard formulation, leveraging its expertise in BCI technology and establishing a comprehensive system for research, clinical application, and results transformation [1] Group 2 - The policy environment is favorable for the BCI industry, as the 14th Five-Year Plan emphasizes the cultivation of emerging and future industries, with BCI officially included as a key development area [1] - The domestic BCI industry is currently experiencing a critical phase of technological iteration and expansion of application scenarios, with both invasive and non-invasive technology paths being developed simultaneously [1] - Non-invasive technology, which utilizes devices like EEG caps for safe and convenient brain signal collection, is more suitable for widespread application in health monitoring and rehabilitation compared to invasive methods that require surgical implantation [2]

Group 1 - The A-share market has seen a significant increase in institutional research activities, with 1,357 institutions conducting approximately 4,897 research sessions on listed companies as of January 18, 2026 [1] - Key focus areas for research include information technology, industrial machinery, and healthcare, particularly in advanced technologies such as brain-computer interfaces, semiconductors, robotics, and solid-state batteries [1] Group 2 - Companies like Henan Xiangyu Medical Equipment Co., Ltd., Beijing Haitan Ruisheng Technology Co., Ltd., and Jiangsu Aipeng Medical Technology Co., Ltd. have been heavily researched, each receiving over 100 institutional inquiries [2] - Institutions are particularly interested in the feasibility of technologies, commercialization timelines, and policy alignment, with specific inquiries directed at brain-computer interface products and rehabilitation robotics [3] Group 3 - Foreign institutions have also been actively researching A-share companies, with notable interest in semiconductor materials and ultrasonic welding equipment, indicating a recognition of China's capabilities in high-end manufacturing [4] - Companies such as Anji Microelectronics Technology Co., Ltd. and Guangdong Aopute Technology Co., Ltd. have attracted high-density foreign institutional research, reflecting their strong R&D investment and visibility of orders [4] Group 4 - UBS analysts indicate that semiconductor equipment companies are likely to receive orders from advanced process production, with a capacity preparation cycle of approximately 2 to 8 quarters [5] - Despite the early market response for semiconductor equipment companies, investors tend to focus on larger market opportunities, leading to widespread interest in computing and wafer manufacturing sectors [5]

Group 1: Institutional Research Activity - A total of 316 listed companies have disclosed institutional investor research records this year [1][2] - Xiangyu Medical received the highest number of institutional inquiries, totaling 208 [2][3] - Multiple prominent institutions have intensively researched SF Holding, with 35 institutions focusing on it this year [4][6] Group 2: Key Companies and Their Focus Areas - The top ten A-share companies by the number of institutional inquiries include Xiangyu Medical, Haitan Ruisheng, and Aipeng Medical, with inquiries ranging from 132 to 208 [3] - SF Holding has been a focal point for several well-known fund companies, including Huaxia Fund and E Fund, indicating strong interest in its strategic partnership with Jitu Express [4][6] Group 3: Strategic Developments - SF Holding and Jitu Express announced a strategic mutual shareholding agreement with an investment amount of HKD 8.3 billion [8] - The collaboration between SF Holding and Jitu Express has expanded across various levels, enhancing service stability and customer satisfaction in both domestic and international markets [7] Group 4: Brain-Computer Interface Focus - The brain-computer interface sector has gained significant market attention, with companies like Xiangyu Medical and Aipeng Medical actively developing products in this area [10][11] - Xiangyu Medical plans to upgrade 27 core products by mid-2026 and launch nearly 100 brain-computer interface products by the end of 2026 [10] - Aipeng Medical is exploring investments in brain-computer interface technologies, focusing on clinical applications for various mental health conditions [11]

Core Insights - Institutional enthusiasm for researching listed companies remains high, with 316 companies disclosing investor research records this year [1][2] - The brain-computer interface sector has seen increased attention from institutional investors, with companies like Xiangyu Medical and Aipeng Medical leading in research inquiries [11][12] Group 1: Institutional Research Activity - A total of 316 listed companies have disclosed institutional investor research records this year, with Xiangyu Medical receiving the highest number of inquiries at 208 [2][3] - Other companies with significant institutional interest include Haitan Ruisheng (207 inquiries), Aipeng Medical (142 inquiries), and Shiji Technology (132 inquiries) [3] - Notably, multiple prominent funds have shown concentrated interest in SF Holding, with 35 institutions conducting research on the company [5][6] Group 2: SF Holding and Strategic Partnerships - SF Holding and Jitu Express announced a strategic mutual shareholding agreement on January 15, with an investment transaction amounting to HKD 8.3 billion [9] - The partnership aims to enhance operational synergies, utilizing SF's delivery network in domestic markets and Jitu's established networks in international markets like the Philippines and Saudi Arabia [8] - SF Holding's stock price was reported at CNY 38.81 per share, with a market capitalization of CNY 194.1 billion as of January 16 [10] Group 3: Brain-Computer Interface Developments - Xiangyu Medical plans to upgrade 27 core products by June 2026, integrating brain-computer interface technology to transform passive rehabilitation devices into active ones [11] - Aipeng Medical is focusing on exploring brain-computer interface investments aligned with its strategic direction, emphasizing research in sensors, electrodes, and clinical applications for mental health disorders [12]

2026 年 1 月 18 日 总量研究 市场或转为震荡上行 ——金融工程市场跟踪周报 20260118 要点 本周市场核心观点： 本周（2026.01.12-2026.01.16，下同）市场涨跌分化，成长风格指数震荡收涨， 红利风格指数表现垫后。1 月 14 日中午，经证监会批准，沪深北交易所发布通 知调整融资保证金比例，当日下午市场表现急转直下，指数出现回调。 市场情绪方面，当前主要宽基指数量能仍处高景气区间，量能观点仍积极；主要 宽基指数及宽基指数 ETF 成交量 PCR 震荡回升，衍生品投资者交易情绪小幅降 温。后市或从趋势性上行转向震荡上行，中长线持续看好"红利+科技"配置主 线，短线科技或仍占优。 本周市场各指数涨跌不一，上证综指下跌 0.45%，上证 50 下跌 1.74%，沪深 300 下跌 0.57%，中证 500 上涨 2.18%，中证 1000 上涨 1.27%，创业板指上 涨 1.00%，北证 50 指数上涨 1.58%。 截至 2026 年 1 月 16 日，宽基指数来看，中证 500、中证 1000、创业板指处于 估值分位数"适中"等级，上证指数、上证 50、沪深 300 处于估值 ...

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [6][13]. Core Insights - Merge Labs has successfully completed a seed round financing of approximately $250 million, achieving a valuation of $850 million. This financing was led by OpenAI, with its CEO Sam Altman participating as a co-founder and investor. Unlike mainstream brain-machine interface technologies, Merge Labs focuses on a non-invasive or minimally invasive approach centered on ultrasound, bypassing the traditional "electrode-neuron" paradigm [3][4]. - The brain-machine interface market is projected to grow rapidly, with the global market size expected to reach approximately $2.62 billion in 2024 and $2.94 billion in 2025, potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.35% over the next decade. In China, the market size is anticipated to be 3.2 billion yuan in 2024, increasing to 6.14 billion yuan by 2028 [5]. Summary by Sections Investment Highlights - Merge Labs' ultrasound-based technology aims to balance between non-invasive (safe but limited resolution) and invasive (clear signals but with surgical risks and ethical concerns) methods. The unique potential of ultrasound's deep penetration and "soft interface" concept is highlighted, although the technology is still in the laboratory research phase and faces multiple unresolved challenges [4]. Market Outlook - The report emphasizes the strategic importance of brain-machine interfaces as a key sector in the "14th Five-Year Plan," aiming to drive new economic growth points. The industry is expected to gain momentum over the next decade, potentially creating a new high-tech industry in China [5]. Recommended Companies - The report suggests monitoring companies such as Rock Mountain Technology, Hanwei Technology, Sanbo Brain Science, Innovation Medical, Dongfang Zhongke, Xiangyu Medical, Entropy Technology, Chengyitong, Weisi Medical, Meilan De, Aipeng Medical, and Beiyikang for potential investment opportunities [5].

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

1月16日，A股三大指数集体下跌。截至收盘，沪指跌0.26%，报4101.91点，深成指跌0.18%，报14281.08点，创业板指跌 0.2%，报3361.02点。从板块行情上来看，今日表现较好的是第四代半导体、光刻机（胶）和中芯概念，而拼多多概念、天 基互联和快手概念等板块下跌。 基金经理是一只基金产品最核心的成员，能决定一只基金的投资方向、投资策略以及投资风格，基金经理出色的择时选股 能力和调研预测能力是基金业绩的有力保证，所以基金经理是投资者在选择基金产品时的重要依据。基金经理的变动很大 程度上会影响到基金产品未来的表现，是一个需要特别关注的信息。1.16日共有20位基金经理发生任职变动。 根据巨灵统计的数据，近30天（12.17-1.16）共有579只基金产品的基金经理发生离职。其中今天（1.16）日有15只基金产 品发布基金经理离职公告，涉及4名基金经理。从变动原因上来看，有3位基金经理是由于工作变动而从管理的7只基金产品 中离职。有1位基金经理是由于个人原因而从管理的8只基金产品中离职。 | | | 基金代码 | 公告日期 | 1 | | | | --- | --- | --- | --- | ...

有投资者在互动平台向 翔宇医疗提问：目前公司的 脑机接口项目已进入多少家医疗机构？翔宇医疗回 复称，公司相关产品已进入600多家三甲医院，2026年目标覆盖超千家三甲医院，商业化进程和临床落 地加速。 ...